Diabetes Mellitus, Type 1 Clinical Trial
— PRIFENOfficial title:
Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy of Phenofibrate Treatment on the Functions of Beta Cells in Children and Adolescents With Newly Diagnosed of Type 1 Diabetes.
The goal of this clinical trial is to evaluate of the effect of phenofibrate on the functions of beta cells in children with new diagnosis of type 1 diabetes. The main question it aims to answer is: whether phenofibrate may prolong residual beta-cell function therefore own insulin secretion. Participants will be asked to take a phenofibrate or identically appearing placebo (a neutral substance), orally, once daily, for 12 months with no knowledge what is administred to them. They will be invited for follow-up visits including blood tests every 3 months. Researchers will be monitoring the two groups for the safety of the phenofibrate, and at the trial end they compare the residual insulin secretion results in two groups.
Status | Recruiting |
Enrollment | 102 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 17 Years |
Eligibility | Inclusion Criteria: Subjects who meet all of the following criteria are eligible to participate in this study: 1. Subject or Legally accepted representative (LAR) able to understand and provide signed informed consent. Assent is also required of adolescents and children. - LAR of subjects = 17 years sign the "Information Leaflet and ICF for the Parent/Legal Guardian of Minor Subject". - Adolescents from 10-15 years sign "Children Assent form". - Adolescents from 16-17 years sign "Adolescent Assent form". 2. Age =10 and = 17 years. 3. Diagnosis of type 1 diabetes within 8 weeks before randomization (V0 visit) based on positive autoantibody (minimum 1 among: GADA, IA2A, ZnT4, IAA) and symptoms of type 1 diabetes according to the criteria of the Polish Diabetes Association (1 of the following): - symptoms of diabetes and blood glucose = 200 mg / dl (= 11.1 mmol/l), - when no symptoms or when diabetes symptoms are present and random glucose <200 mg/dl (<11.1 mmol/l) - then confirmation of the diagnosis is fasting blood glucose in 2 measurements = 126 mg/dl (= 7.0 mmol/l); each test must be performed on a different day, - in the absence of symptoms of hyperglycaemia and random glycaemia = 200 mg/dl (11.1 mmol/l), fasting glucose = 126 mg/dl (7.0 mmol/l) is a confirmation of the diagnosis, - if once or twice fasting blood glucose is 100-125 mg / dl (5.6-6.9 mmol/l), or if fasting blood glucose is below 100 mg/dl (5.6 mmol/l) ) exists, If there is a reasonable suspicion of impaired glucose tolerance or diabetes mellitus, an oral glucose tolerance test (OGTT) should be performed. At the 120th minute of the OGTT, blood glucose = 200 mg/dl (11.1 mmol/l) confirms the diagnosis of diabetes. 4. Male or nonpregnant and nonlactating female who is abstinent or agrees to use effective contraceptive methods throughout the course of the study. Acceptable birth control methods are the following: - Intrauterine device in place for at least 3 months. - Use of condom or diaphragm with spermicide for at least 14 days prior to the Visit 0 visit and through study completion. - Stable hormonal contraceptive for at least 2 months prior to the Visit 0 and continuing through study completion. 5. Females (menstruating) must have a negative urine beta-human chorionic gonadotropin hormone (hCG) pregnancy test at Visit 0. Exclusion Criteria: Subjects who meet any of the following criteria are not eligible to participate in this study: 1. Age under 10 or over 17. 2. Lack of consent of at least one the guardian LAR to participate in the study. 3. Treatment with any oral or injected anti-diabetic medications other than insulin. 4. The Subject or close Subject's family history, past or present of allergic or hypersensitivity reactions to fenofibrate or any of the excipients (including patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption). 5. Severe hypersensitivity reaction to any other drug. 6. Subjects with current or history of clinically significant renal impairment. 7. Subjects with current or history of clinically significant hepatic impairment. 8. Subjects with or history of significant gastrointestinal disease including celiac disease, gastroparesis, another disorder of intestinal absorption or motility. 9. Subject with current or history of gall bladder disease. 10. Present or history of chronic or acute pancreatitis, except acute pancreatitis due to severe hypertriglyceridaemia. 11. Photosensitivity or phototoxic reactions after the use of fibrates or chemically related substances, e.g. ketoprofen. 12. Subjects who tested positive for pregnancy at screening and V0 visit or who are currently breastfeeding. 13. Low blood albumin defined as clinically significant by investigator. 14. Patients with pre-disposing factors for myopathy and/or rhabdomyolysis, including personal and familial history of hereditary muscular disorders. Unexplained persistent elevated creatine phosphokinase levels considered clinically significant by the investigator. 15. The presence of circumstances that the Investigator considers problematic when obtaining informed consent or meeting the study guidelines, or that may invalidate the interpretation of test results or expose Subjects to unnecessary risk. 16. Inability or unwillingness to comply with study procedures. 17. Any medical condition or treatment the Investigator believes may expose the Subject to unnecessary risk during the study. 18. Participation in interventional or other drug research studies which could affect the objectives of this study. |
Country | Name | City | State |
---|---|---|---|
Poland | Clinical department of pediatric diabetology and paediatrics, DSK UCKWUM | Warsaw | Mazowieckie |
Poland | Diabetology Department, Children's Memorial Health Institute | Warsaw | Mazowieckie |
Lead Sponsor | Collaborator |
---|---|
Medical University of Warsaw | Children's Memorial Health Institute, Poland |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in AUC in C-peptide stimulation test | Assessment of pancreatic beta cell function by comparing the area under the curve (AUC) in the C-peptide stimulation test: Change in the mean insulin secretion measured on the basis of the C-peptide area under the curve in the stimulation test | 12 months | |
Secondary | Differences in C-peptide concentration in the stimulation test: change in the insulin secretion measured on the basis of the fasting C-peptide concentration | Fasting C-peptide concentration in the stimulation test | 0, 6, 12 months | |
Secondary | Differences in parameters of diabetes control | HbA1c | 0,3,6,9,12 months | |
Secondary | Daily insulin requirement | Daily insulin requirement/kg of body mass | 0,3,6,9,12 months | |
Secondary | Interleukins | IL1, IL2, IL10, TNF alpha, IFN gamma | 0,6,12 months | |
Secondary | Adverse Events occurence | Safety will be evaluated through assessment of AEs, vital signs, physical examinations, USG findings, and laboratory evaluations. Any clinically significant laboratory occurring after study drug initiation must be reported by the investigator as an AE and/or SAE, as appropriate, and must be followed by additional laboratory evaluations until they return to normal range, stabilize, or until the change is no longer clinically relevant. All safety analyses will be conducted using the Safety Analysis Set. Adverse event data will be presented and tabulated according to MedDRA classification. | 0,3,6,9,12 months | |
Secondary | Differences in C-peptide concentration in the stimulation test: change in the insulin secretion measured on the basis of the fasting C-peptide concentration | Maximum C-peptide concentration | 0,6,12 months | |
Secondary | Diabetes control and glucose fluctuations | Mean blood glucose with standard deviation | 0,3,6,9,12 months | |
Secondary | Differences in glucose fluctuations | Glucose variability index (CV%) | 0,3,6,9,12 months | |
Secondary | Parameter of glucose fluctuations | Time in range 70-180mg/dl | 0,3,6,9,12 months | |
Secondary | Difference in autoantibodies | Difference in anti-insulin IAA antibodies, antibodies against glutamic acid decarboxylase (GADA), antibodies to tyrosine phosphatase (IA2A), anti-zinc transporter antibodies 8 determination. | 0,6,12 month | |
Secondary | Genetical analysis | WES Whole Exome Sequencing and HLA | 1 per study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT03605329 -
Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Recruiting |
NCT06050642 -
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
|
N/A | |
Completed |
NCT05107544 -
Metabolic, Physical Fitness and Mental Health Effects of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04443153 -
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
|
N/A | |
Completed |
NCT04569994 -
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
Completed |
NCT04089462 -
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
|
N/A | |
Completed |
NCT03143816 -
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
|
Phase 4 | |
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Completed |
NCT04042207 -
Diabeloop for Highly Unstable Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06068205 -
COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS
|
||
Active, not recruiting |
NCT04974528 -
Afrezza® INHALE-1 Study in Pediatrics
|
Phase 3 | |
Completed |
NCT04530292 -
Home Intervention and Social Precariousness in Childhood Diabetes
|
N/A | |
Completed |
NCT05428943 -
OPT101 in Type 1 Diabetes Patients
|
Phase 1 | |
Recruiting |
NCT03988764 -
Monogenic Diabetes Misdiagnosed as Type 1
|
||
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A | |
Not yet recruiting |
NCT06422494 -
The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II
|
N/A |